The Chinese pharmaceutical sector growth slowed further in 2015 to around 10% under the shadow of numerous challenges mostly stemmed from the troubled Chinese economy, regulatory shakeups, cost containment measures and healthcare reform turbulences.
Many drug company executives are still bullish about China's long-term growth prospects and drug spending is expected by IMS to reach as much as US$185 billion by 2018. But the short-term picture is proving less rosy, with reforms in the hospital sector impacting prescribing and price pressures increasing for most drugs.
Chinese experts warned recently that the pharmaceutical industry is facing a more complex Chinese marketplace in 2016. There will be lots of uncertainties, unbalances and frailty ahead. The future outlook is mixed, while most analysts agree that the market will keep on growing, but at a slower rate, continuing the trend which started two years ago.
Other than growing challenges on the ground in China, there are success stories from all categories of players, whether they are foreign or local, large or small, newcomer or established, private or state-owned. However, to be one of the success stories require a thorough understanding of the sector, ability to face and tackle challenges, flexibility to deal with changes, and skills to maneuver through complex situations.
To cater for the growing needs of headquarter pharmaceutical executives for better understanding of the Chinese market, the Seminar was launched in 2009 by Pharma China, the most trusted English media and source of business intelligence covering the Chinese pharmaceutical / biopharmaceutical industry and market, and AmIntell, the organizer of Pharma CI Conference and Pharma Market Research Conference.
"Pharma China Seminar - Building Success in China's Pharma Sector" is a one-day seminar providing insights into contemporary trends/issues and the most important aspects of the Chinese pharmaceutical industry and marketplace today. This year’s event will focus on healthcare policies, drug regulations, market access and strategic issues as well as potential impacts of latest and upcoming policy changes on the Chinese pharma industry. In addition, contemporary trends of M&As, R&D and licensing, business hotspots and e-commerce, as well as future market outlook will be explored and discussed.
On the basis of our successful experience with the event in the past five years, Pharma China Seminar 2016 will refocus its agenda to provide more in-depth coverage of and strategic insights into the following key aspects of Chinese pharma business including 1) latest trends and issues in drug regulation and healthcare policies, 2) impacts of deepening healthcare reform on the pharma industry and changing business models; 3) changing dynamics in Chinese pharma and evolving new business model, 4) changing role of China in global supply chain of pharma companies; 5) R&D, partnership and licensing trends & strategies; 6) dynamic healthcare and disease trends, 7) licensing, business hotspots and e-commerce, 8) emerging IP/legal/compliance issues, 9) new opportunity areas such as biosimilars, and 10) pharma/healthcare market outlook.
At least ten leading experts of the Chinese pharmaceutical/healthcare sector with different specialization will share their expertise and knowledge through exclusive data, detailed analysis, case studies and interactive panel discussions.
Who should attend?